Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01454570 · ClinicalTrials.gov registry record · NA
The ReWalk Exoskeletal Walking System for Persons With Paraplegia
A NA study of Paraplegia, sponsored by James J. Peters Veterans Affairs Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT01454570: Completed NA study of Paraplegia, sponsored by James J. Peters Veterans Affairs Medical Center.
NCT01454570 is a NA study of Paraplegia that has completed, run by James J. Peters Veterans Affairs Medical Center. The registered enrollment target is 19 participants, below the 66-participant average among 8 other Paraplegia trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01454570, a NA study of Paraplegia, has completed, sponsored by James J. Peters Veterans Affairs Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
It is well appreciated that an extreme sedentary lifestyle from paralysis, contributes to many secondary medical problems such as diabetes and insulin resistance, obesity, constipation, poor blood pressure regulation, cardiovascular disease, reduced quality of life, and more. The ReWalk-I exoskeleton walking device permits investigation of the potential benefits of frequent upright posture and walking on many of the secondary consequences of spinal cord injury. The researchers are investigating the ability of persons with paraplegia to learn to stand and walk with the ReWalk-I and the effects of being upright and walking on several of these secondary medical consequences of spinal cord injury.
Primary Outcome
1\. To determine efficacy for mobility defined as the ability to perform the following with the ReWalk-I exoskeletal system, without staff assistance: 1. Sit-to-stand, 2. Stand-to-sit, 3. Standing balance for 1 minutes with both crutches, 4. Standing balance for 30 seconds with one crutch, 5. Ten meter walk in ≤2 minutes, 6. Walk ≥30 meters in 6-minutes, and 7. Ascend, turn around and descend 4 stairs in 5 minutes.
Conditions Studied
Interventions
- DEVICE powered exoskeleton
Study Locations (1)
New York
- James J. Peters Veterans Affairs Medical Center; Center of Excellence for the Major Consequences of SCI. - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2011-02 |
| Est. Completion | 2015-08-08 |
| Phase | NA |
What the finished NCT01454570 record still lists
NCT01454570 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 66-participant average among 8 other Paraplegia trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Paraplegia appearing as the primary indexed condition, and to 1 intervention - of which powered exoskeleton is the first listed.
NCT01454570 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01454570 about?
NCT01454570 is a clinical study titled "The ReWalk Exoskeletal Walking System for Persons With Paraplegia". It is well appreciated that an extreme sedentary lifestyle from paralysis, contributes to many secondary medical problems such as diabetes and insulin resistance, obesity, constipation, poor blood pressure regulation, cardiovascular disease, reduced quality of life, and more. The ReWalk-I exoskeleto...
What is the current status of trial NCT01454570?
This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2011-02. Estimated completion is 2015-08-08.
What conditions does trial NCT01454570 study?
This clinical trial studies the following conditions: Paraplegia.
What interventions are being tested in trial NCT01454570?
The interventions under investigation include: powered exoskeleton (DEVICE).
Who is sponsoring clinical trial NCT01454570?
This trial is sponsored by James J. Peters Veterans Affairs Medical Center, which has 39 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01454570 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Paraplegia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01454570's enrollment target sits among peer trials
19 6th of 8 higher than 3 of 8 other Paraplegia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Paraplegia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of an Advanced Lower Extremity Neuroprostheses
RECRUITING · NA
-
A Neuroprosthesis for Seated Posture and Balance
RECRUITING · NA
-
Virtual Peer Coaching in Manual Wheelchair Skills
RECRUITING · NA
-
Extracorporeal Shockwave Therapy for Spasticity in People With Spinal Cord Injury
RECRUITING · NA
-
Improving Clinician Capacity to Provide Interventions for Manual Wheelchair Users
ACTIVE NOT RECRUITING · NA
-
Short-Term Transcutaneous or Epidural Spinal Stimulation for Enabling Motor Function in Humans With SCI
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia